Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali Canbay

Showing results (1-10 of 327) with videos related to

Pageof 33
Sort By:
Medizinische Klinik (Munich, Germany : 1983)|June 29, 2006
[Specific therapy in acute liver failure]Ali Canbay, Guido Gerken
MMW Fortschritte Der Medizin|November 22, 2024
Aline Gottlieb, Ali Canbay
Gut|January 22, 2018
Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implicationHeike Bantel, Ali Canbay
Cells|November 2, 2019
Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) ProgressionAline Gottlieb, Ali Canbay
Visceral Medicine|October 23, 2018
Intensive Care Therapy for Patients with Advanced Liver DiseasesAntonios Katsounas, Ali Canbay
Hepatobiliary Surgery and Nutrition|June 23, 2021
Alcohol consumption leads to loss of healthy life, but the <i>ADH1B*2</i> allele may still protect from NASHGuillermo Mazzolini, Ali Canbay
Annals of Hepatology|April 21, 2017
Liver Transplantation as Cure of Hepatocellular Carcinoma: It is not a Matter of Time, it is a Matter of Tumor BiologyChristoph Jochum, Ali Canbay
Digestive Diseases (Basel, Switzerland)|July 18, 2018
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver DiseaseRoger F Butterworth, Ali Canbay
Drugs|February 2, 2019
L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver DiseaseAli Canbay, Jan-Peter Sowa
Zeitschrift Fur Gastroenterologie|January 9, 2023
Ali Canbay, Jan-Peter Sowa
Pageof 33

Showing results (1-10 of 327) with videos related to

Sort By:
Pageof 33
Medizinische Klinik (Munich, Germany : 1983)|June 29, 2006
[Specific therapy in acute liver failure]Ali Canbay, Guido Gerken
MMW Fortschritte Der Medizin|November 22, 2024
Aline Gottlieb, Ali Canbay
Gut|January 22, 2018
Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implicationHeike Bantel, Ali Canbay
Cells|November 2, 2019
Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) ProgressionAline Gottlieb, Ali Canbay
Visceral Medicine|October 23, 2018
Intensive Care Therapy for Patients with Advanced Liver DiseasesAntonios Katsounas, Ali Canbay
Hepatobiliary Surgery and Nutrition|June 23, 2021
Alcohol consumption leads to loss of healthy life, but the <i>ADH1B*2</i> allele may still protect from NASHGuillermo Mazzolini, Ali Canbay
Annals of Hepatology|April 21, 2017
Liver Transplantation as Cure of Hepatocellular Carcinoma: It is not a Matter of Time, it is a Matter of Tumor BiologyChristoph Jochum, Ali Canbay
Digestive Diseases (Basel, Switzerland)|July 18, 2018
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver DiseaseRoger F Butterworth, Ali Canbay
Drugs|February 2, 2019
L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver DiseaseAli Canbay, Jan-Peter Sowa
Zeitschrift Fur Gastroenterologie|January 9, 2023
Ali Canbay, Jan-Peter Sowa
Pageof 33